



## Supplementary Materials




**Figure S1.** Erlotinib dose-response curves in 2D and 3D cultures (0.15% and 0.5% RAD16-I) of BxPC-3, PANC-1 and hNDF cells.




**Figure S2.** EGFR degradation with increasing concentrations of erlotinib in EGF-incubated BxPC-3 cells in 3D RAD16-I scaffolds. (a) Western blot bands of EGFR in BxPC-3 cultured in soft and stiff RAD16-I scaffold with different erlotinib concentrations; (b) Densitometry of bands showed in (a). GAPDH was used as an internal control. Statistical differences are indicated as \*\* for  $p < 0.01$ , \*\*\* for  $p < 0.001$  and \*\*\*\* for  $p < 0.0001$ .


**(a)** PANC-1 cells; 2D and 3D; 16 h Erlotinib/EGF




**(d)** BxPC-3 cells; 2D and 3D; Erlotinib dose-response




**(b)** BxPC-3 cells; 2D and 3D; 16 h Erlotinib/EGF




**(c)** hNDF cells; 2D and 3D; 16 h Erlotinib/EGF



**(e)** PANC-1 cells; 3D 0.15% RAD; BafA1/MG132



**(f)** BxPC-3 cells; 3D 0.15% RAD; BafA1/MG132



**Figure S3.** Uncropped western blot images. Blots from Figure 7 (a,b,c), Figure S2 (d) and Figure 8 (e,f).